GlassScriptPhysician profile
Samuel J King
NPI 1174550867
$7,718.10
in general payments reported to CMS, 2019-2025
39 companies · $1,805 in 2025
The $1,805 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $883 · 2020: $755 · 2021: $1,003 · 2022: $812 · 2023: $922 · 2024: $1,537 · 2025: $1,805.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,264.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,264.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,219.91 | 2019-2025 | Airsupra, Farxiga, Brilinta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $828.33 | 2019-2025 | Jardiance |
| Abbvie INC. | $807.64 | 2021-2025 | |
| Glaxosmithkline, LLC. | $677.22 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $546.39 | 2019-2021 | |
| Lilly USA, LLC | $438.13 | 2020-2025 | Jardiance, Mounjaro |
| Abbott Laboratories | $347.81 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Grifols USA, LLC | $305.37 | 2024-2025 | Prolastin-C Liquid |
| Novo Nordisk INC | $283.13 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Sanofi-Aventis U.S. LLC | $195.83 | 2020-2023 | |
| Novartis Pharmaceuticals Corporation | $176.49 | 2022-2024 | |
| Otsuka America Pharmaceutical, INC. | $174.47 | 2024-2025 | Jynarque |
| Esperion Therapeutics, INC. | $168.35 | 2021 | |
| Boston Scientific Corporation | $149.52 | 2019-2023 | Watchman Access System |
| Allergan, INC. | $145.96 | 2019-2020 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.